home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

186.42 +3.45 (+1.89%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

24 25 Next >

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 05, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

May 01, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) ↗

April 29, 2025

Via Benzinga

Axsome Therapeutics to Participate in Upcoming Investor Conferences

April 22, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) ↗

February 27, 2025

Via Benzinga

SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT)

April 14, 2025

From Grabar Law Office

Via GlobeNewswire

Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Investigates

April 11, 2025

From Grabar Law Office

Via GlobeNewswire

ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions

April 08, 2025

From Grabar Law Office

Via GlobeNewswire

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

April 08, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

April 07, 2025

Via Benzinga

April 07, 2025

From Grabar Law Office

Via GlobeNewswire

SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); and Maison Solutions

April 04, 2025

From Grabar Law Office

Via GlobeNewswire

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

April 04, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Stocks Edge Higher Despite Trade, Economic Jitters ↗

April 01, 2025

Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data.

Via Talk Markets

Topics Stocks / Equities

Why Shares of Axsome Therapeutics Slumped Today ↗

April 01, 2025

Via The Motley Fool

Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week ↗

April 01, 2025

The company posted mixed results for its depression treatment, noting it appears to work in a smaller patient group.

Via Investor's Business Daily

Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder ↗

April 01, 2025

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients supports plans for a new study in 2025.

Via Benzinga

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

April 01, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday ↗

March 27, 2025

Via Benzinga

Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views ↗

March 27, 2025

Via Benzinga

Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗

March 25, 2025

Via The Motley Fool

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. ↗

March 25, 2025

The company is working on a non-stimulant approach to treating ADHD.

Via Investor's Business Daily

Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal ↗

March 25, 2025

Axsome's solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile.

Via Benzinga

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

March 25, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

March 05, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

March 03, 2025

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Participate in Upcoming Investor Conferences

February 26, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs ↗

February 24, 2025

Axsome's Symbravo outperformed oral CGRP inhibitors in a Phase 3 trial, improving migraine pain relief, symptom control, and return to daily activities.

Via Benzinga

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

February 24, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com